Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Collaborative research and development license agreement under which the Company granted Pharmsynthez an exclusive license to develop and commercialize six product candidates based on PolyXen and ImuXen technology in certain territories
Stock subscription and collaborative development agreement (Co-Development Agreement) granting exclusive licenses in SynBio Market and outside it; assigned to Pharmsynthez effective December 20, 2021
Loan agreement under which the Company advanced Pharmsynthez up to $500,000 at 10% interest, guaranteed by its subsidiaries and secured by Company stock; repaid May 2023
Clinical trial services agreement to advance the systemic DNase I technology program in Israeli medical centers
Consulting agreement, effective January 1, 2025, for consulting services to the DNase-based oncology program
Loading...
